Royalty Report: Drugs, Weight Loss, Personal Care – Collection: 121792


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Weight Loss
  • Personal Care
  • Healthcare
  • Diet System
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 121792

License Grant
The Company obtained worldwide manufacturing and marketing rights to the formula, NxTrim.
License Property
NxTrim is a weight loss management and weight loss supplement.
Field of Use
This agreement pertains to the drug industry relating to weight loss.

IPSCIO Record ID: 114672

License Grant
The Company will sublicense a portion of Licensor’s technology relating to kinase inhibition.
License Property
Kinases are enzymes that regulate essential cellular processes.
Field of Use
Licensee is a company specializing in the development of a weight loss drug therapy.

IPSCIO Record ID: 211879

License Grant
Licensor grants to the Licensee of England and Wales an exclusive license, with the right to grant sublicenses under the patents and know-how to make, have made, use, sell, offer for sale, and import Licensed Product, in the field, in the territory.

Licensor grants the right of first refusal to obtain an exclusive license in the territory to make, have made, use, sell, offer for sale, and import product, with the right to grant sublicenses, in respect of all new product development concerning or relating to appetite suppression, meal replacement for weight management, weight loss and/or weight management not covered by patents or know-how and in respect of which Licensor intends to use a Third Party to further develop and/or commercialize such new product, upon terms to be mutually negotiated by the parties in good faith.

Licensor shall grant an Exclusive Period of ninety days following notification of each such new product development to negotiate and agree the terms of an exclusive license.

License Property
Licensed product means all products concerning or relating to appetite suppression, meal replacement products used in weight management, weight loss and/or weight management under development by Licensor as of the Effective Date and/or marketed by Licensor under the brand name Satietrol(R).

Satietrol(R) js patented appetite control technology.  Satietrol works by stimulating the body's own satiety peptide, cholecystokinin (CCK). Prescription drugs that work by stimulating satiety peptides may be the wave of the future for weight control.

Patent No. 6,207,638 – Nutritional Intervention Composition for Enhancing and Extending Satiety

Field of Use
The field shall mean all human uses of the appetite suppression, meal replacement products.

IPSCIO Record ID: 273411

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, subject to the terms, conditions and restrictions of this agreement, the exclusive, worldwide right and sublicenseable license under the Licensor Intellectual Property rights, until the end of the term for which the Licensor Patent rights are granted, unless this agreement shall be sooner terminated according to the terms hereinafter provided to
(a)  develop, make, have made, import, use, lease, offer for sale, sell, and distribute Licensed Products;
(b)  develop, make, have made, import, use, lease, offer for sale, sell, and distribute Licensed Processes
(c)  develop, make, have made, perform, provide, import, use, lease, offer for sale, sell, and distribute Licensed Services; and/or
(d)  practice and use the Licensor Intellectual Property rights, other than Licensor Patent rights, and to use the Licensor materials, insofar as such practice and use is required to carry out the activities under subsections (a)-(c) above.
License Property
The Intellectual Property rights relating to technology which enhances human weight loss associated with the use of certain therapeutics.

Licensed Product means any product or part thereof containing mirtazapine or setiptiline in any form, (including, without limitation, any and all enantiomers, analogs, derivatives and salts thereof) used in combination with one or more active ingredients.

Licensor Patent Rights (Duke Patents)
Serial No. 60/535,799 – Method of reducing weight gain risk associated with antidepressant therapy.
Serial No. 60/567,896 – Compositions for affecting weight loss.
Serial No. 60/616,393 – Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss.

Field of Use
The technology sublicensed relates to the use of zonisamide with either of two specified therapeutics mirtazapine and setipiline.

One of the specified uses under the agreement is development program for obstructive sleep apnea.

IPSCIO Record ID: 138053

License Grant
Licensor is granting an exclusive license, or transferring intellectual property, to develop, manufacture and commercialize lorcaserin in all countries and territories of the world.
License Property
The agreement transfers certain patents, regulatory approvals, samples, records, know-how related to BELVIQ, trademarks, including the trademarks BELVIQ, BELVIQ XR and VENESPRI, and agreements with distributors of BELVIQ in South Korea, Taiwan and Israel, and domain names related to BELVIQ.

BELVIQ refers to each of the formulations of lorcaserin approved for weight management.  In Mexico it is marketed under the brand name VENESPRI®.

Field of Use
These product formulations are used in the weight-loss industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.